Governance with
proven expertise
Philip Just Larsen
MD, PhD
Chair
He is currently CEO of Sixpeaks Bio AG and was previously Senior Vice President, Global Head of Pharma Research and Early Development Precision Medicine at Bayer AG. Philip has held R&D leadership roles at several global pharmaceutical companies, including Novo Nordisk, Eli Lilly, AstraZeneca, and Sanofi.
As CSO for Diabetes and Obesity at Eli Lilly, he led the initiation of the dual incretin agonist programmes that resulted in tirzepatide and mazdutide.
He holds an MD and a PhD in neuroscience from the University of Copenhagen.
Mark Currie
BSc, PhD
Independent
Additionally, he is a venture partner at Iaso Ventures, responsible for investments in therapeutics. In addition to his role at Antag, Mark is on the board of Sea Pharmaceuticals and chairs the Scientific Advisory Boards (SABs) for Scaffold Therapeutics and Wild Bio. His previous board memberships include Science Exchange and the Foundation for Research at the Medical University of South Carolina. Mark holds a PhD in Cell Biology from Wake Forest University School of Medicine and a BS from University of South Alabama.
Alexander Mayweg
BSc, PhD
Board member
Prior to joining Versant, Alexander spent 14 years at Roche, most recently as Global Head of Chemistry, and held various scientific leadership roles across the organization. Alexander holds a PhD in Organic Chemistry from the University of Oxford, a BSc from Imperial College London, and completed postdoctoral research at Stanford University.
Jørgen Søberg Petersen
MD, PhD, DMSc, MBA
Board member
He has held executive R&D roles at Lundbeck, Zealand Pharma, Merck, and Novo Nordisk, and was a co-founder of Zealand Pharma, where he led the company through to exit.
Jørgen currently serves on the Boards of Acesion Pharma, Engimmune Therapeutics, Breye Therapeutics, Hemab Therapeutics, and Tribune Therapeutics.
He holds an MD and a PhD in Pharmacology from the University of Copenhagen, and an MBA from the Technical University of Denmark.
Amit Shah
MSc, MD
Board member
Amit joined the Board of Antag Therapeutics in November 2024. He is a board-certified equivalent plastic surgeon specialising in microsurgical cancer reconstruction and is currently a Principal at SR One Capital Management.
Prior to joining SR One, he held various roles at GlaxoSmithKline across late-phase clinical development, global medical affairs, and early pipeline commercial strategy.
Amit sits on the venture capital panel of the BioInnovation Institute, Novo Nordisk’s international life sciences incubator, and serves on the Boards of ADARx Pharmaceuticals, Asceneuron, Codify Therapeutics, HotSpot Therapeutics, and River Renal.
He holds an MD from the University of Cambridge.
Jörg Möller
MD, PhD
Chief Executive Officer
Jörg joined Antag Therapeutics as CEO and member of the Board in January 2025, bringing more than 30 years of experience in the pharmaceutical and biotech industry. Prior to Antag, Jörg was the CEO and Executive Director of Benevolent AI. Before that, he was the Executive Vice President and Head of Global Research and Development of LEO Pharma A/S.
Earlier in his career, Jörg held several senior roles at Bayer AG, most recently Executive Vice President, Global Head of Pharmaceutical Research and Development and a member of the Executive Committee of the Pharmaceutical Division. He is currently a member of the Board at Secura Bio and holds an MD from Ruhr-University Bochum Medical School.